Effects of rosiglitazone on contralateral iliac artery after vascular injury in hypercholesterolemic rabbits
Authors:
- Olímpio Ribeiro França NetoONOlímpio Ribeiro França Neto
- Dalton Bertolim PrecomaDPDalton Bertolim Precoma
- Alexandre AlessiAAAlexandre Alessi
- Camila PrimCPCamila Prim
- Ruy FernandoKuenzerCaetano da SilvaRSRuy FernandoKuenzerCaetano da Silva
- Lucia de NoronhaLNLucia de Noronha
- Liz Andréavillela BaronciniLBLiz Andréavillela Baroncini
Open Access
- 16 May 2008
- journal article
- Published by Springer Nature in Thrombosis Journal
- Vol. 6 (1) , 4
Abstract
Background: The objective was to evaluate the effects of rosiglitazone on iliac arteries of hypercholesterolemic rabbits undergoing balloon catheter injury in the contralateral iliac arteries. Methods: White male rabbits were fed a hypercholesterolemic diet for 6 weeks and divided into two groups as follows: rosiglitazone group, 14 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) during 6 weeks; and control group, 18 rabbits without rosiglitazone treatment. All animals underwent balloon catheter injury of the right iliac artery on the fourteenth day of the experiment. Results: There was no significant difference in intima/media layer area ratio between the control group and the rosiglitazone group. Rosiglitazone did not reduce the probability of lesions types I, II, or III (72.73% vs. 92.31%; p = 0.30) and types IV or V (27.27% vs. 7.69%; p = 0.30). There were no differences in the extent of collagen type I and III deposition or in the percentage of animals with macrophages in the intima layer. The percentage of rabbits with smooth muscle cells in the intima layer was higher in rosiglitazone group (p = 0.011). Conclusion: These findings demonstrate that rosiglitazone given for 6 weeks did not prevent atherogenesis at a vessel distant from the injury site.Keywords
This publication has 36 references indexed in Scilit:
- Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonismDiabetes & Vascular Disease Research, 2006
- PPARα, but not PPARγ, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed DyslipidemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- A potent activator of PPARα and γ reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbitsAtherosclerosis, 2005
- The balloon catheter induces an increase in contralateral carotid artery reactivity to angiotensin II and phenylephrineBritish Journal of Pharmacology, 2004
- Vascular hyper-reactivity following arterial balloon injury: distant and delayed effectsBritish Journal of Pharmacology, 2004
- Antioxidative, Antinitrative, and Vasculoprotective Effects of a Peroxisome Proliferator–Activated Receptor-γ Agonist in HypercholesterolemiaCirculation, 2003
- Rosiglitazone Reduces the Accelerated Neointima Formation After Arterial Injury in a Mouse Injury Model of Type 2 DiabetesCirculation, 2003
- Control of Vascular Cell Proliferation and Migration by PPAR-γDiabetes Care, 2001
- Proliferation of smooth muscle cells at sites distant from vascular injury.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990